MD PhD / Prof of Internal Medicine / National Referal Center #autoimmune diseases #SNFMI #GFEV #GEFA @CHUDijon @univbourgogne
Dijon, France
Joined July 2022
- Tweets321
- Following200
- Followers235
- Likes271
Maxime Samson retweeted
✉️Edito
Quelle est la place du Sécukinumab dans la prise en charge de l'artérite à cellules géantes ? Interprétation des résultats de l'étude GCAptAIN et proposition d'inclusion des anti-IL17A dans les recommandations :
sciencedirect.com/science/ar…
Maxime Samson retweeted
Presented at #EULAR2026:
Among patients with relapsed polymyalgia rheumatica, treatment with secukinumab plus a 24-week glucocorticoid taper resulted in a higher percentage of patients with remission than a glucocorticoid taper alone. Full phase 3 REPLENISH trial results: nej.md/3PvmmMO
Editorial: Emerging Era for Polymyalgia Rheumatica and GCA — Interleukin-17A Targeting nej.md/4dB5b5I
Original Article in @NEJMEvidence: Secukinumab for Giant Cell Arteritis (phase 3 GCAptAIN trial) eviden.cc/49CLAj9
@eular_org
ALT Chart from an article published in the New England Journal of Medicine showing results from a phase 3 trial of secukinumab in polymyalgia rheumatica. Two bar graphs depict sustained remission and complete sustained remission at week 52, comparing secukinumab, 300 mg (dark blue bars); secukinumab, 150 mg (light blue bars); and placebo (grey bars). Statistical significance is noted with P<0.001 for each comparison.
Maxime Samson retweeted
📢 NEWS ALERT!
#EULAR has released an update to the recommendations for managing Behçet’s syndrome, reflecting advances in evidence and treatment strategies.
Read the full #eularPressRelease here 👉 pulse.ly/8bgmepplgl
#BehcetsSyndrome #Rheumatology
Maxime Samson retweeted
🔔Alerte nouveau PNDS 🔔
Découvrez le PNDS sur le diagnostic et la prise en charge des péricardites récidivantes :
sciencedirect.com/science/ar…
Avec notre éditorial : "Péricardites : un nouveau paradigme ?"
sciencedirect.com/science/ar…
#PNDS #Guidelines #pericarditis #recurrent
Maxime Samson retweeted
Very important data!
Presented at the 15th European Lupus Meeting:
In patients with SLE without advanced lupus nephritis, obinutuzumab plus standard therapy was superior to placebo plus standard therapy in conferring and sustaining a clinically meaningful reduction in disease activity over 52 weeks. Full phase 3 ALLEGORY trial results: nejm.org/doi/full/10.1056/NE…
#SLEuro | @SLEuroSociety
ALT 15th European Lupus Meeting Original Article | MAR 6, 2026 | NEJM.org Efficacy and Safety of Obinutuzumab in Active Systemic Lupus Erythematosus Figure 1A. Time to First BILAG Flare.
Maxime Samson retweeted
Lancement officiel de Corticomed, l'outil d'aide à la décroissance des corticoides en médecine interne. Gratuit, simple et basé sur les recommandations nationales et internationales. share.google/aVhMWV6wi9Pheni…
Maxime Samson retweeted
💡#GCA epidemiology is fascinating 🤯
Its incidence varies inexplicably with constitutional & environmental factors🌍
➡️Check out our latest SR-MA in @Rheumatol_Int & as we focus on seasonality & latitude influence on #GCA & how both can be connected
🔗 shorturl.at/1kyOL
Maxime Samson retweeted
For anyone interested in #VEXAS check out the 2nd international workshop happening Sept @nyulangone in NYC. @petercgrayson @bhavishap29 @sinisauksav @SophieGeorgin @MikkaelSekeres @thibault_comont @TerrierBen highmarksce.com/nyumc/index.…
Maxime Samson retweeted
🚨🚨🚨 AHHH we have just been granted a 🔓 FREE 50-DAY ACCESS LINK to the expert #consensus on the therapeutic management of RARE systemic #lupus erythematosus manifestations
Can you please re-tweet the link so that a MAXIMUM have access for free 🔄 LINK: authors.elsevier.com/a/1l8og…
Maxime Samson retweeted
Thrilled and honored to speak for this session in Barcelona
As Erdheim-Chester Disease (ECD) becomes more recognized and understood within the medical community, a new challenge is emerging: what happens when a patient’s symptoms don’t follow a predictable pattern, or worse, when ECD isn’t the only condition ...
erdheim-chester.org/keynote-…
Maxime Samson retweeted
Interested in vasculitis? Don’t miss the 6th EUVAS Vasculitis Course! May 21–24, 2025. Trieste, Italy !
Stay up to date with the latest in vasculitis
The course is fully booked for onsite participation. But available online. – register today!
eventi.eve-lab.com/congresso…
Maxime Samson retweeted
Impact of autoantibody status on stratifying the risk of organ involvement and mortality in SSc
⏩1605 patients
⏩ associations between each AAb and internal organ involvement
⏩skin phenotype was not an independent factor
rmdopen.bmj.com/content/10/4…
Maxime Samson retweeted
📢 Nouveau PNDS 2024 : Interféronopathies
Nous sommes ravis d’annoncer la publication du Protocole National de Diagnostic et de Soins (PNDS) 2024 consacré aux interféronopathies !
📄 À lire sur : lnkd.in/ekuqNMAM
#PNDS #Interféronopathies #HAS
Maxime Samson retweeted
@SNFMI_Medical
Soyons fiers de nos jeunes internistes @AJInternistes qui ont brillamment présenté leurs travaux 🤩 et représenté notre spécialité 😍 au congrès international de l'ACR 2024 à Washington 🇺🇸 ! Bravo à tous 👏
Merci à @contactfai2r !
Merci à @SNFMI_Medical !
Maxime Samson retweeted
Glucocorticoids versus glucocorticoids plus cyclophosphamide in eosinophilic granulomatosis with polyangiitis with poor-prognosis factors!
Click here to read or download the article!📢📢📢
sciencedirect.com/science/ar…